- Home
- GLRE vs PSNL Comparison
GLRE vs PSNL Comparison
Compare GLRE & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLRE
- PSNL
- Stock Information
- Founded
- GLRE 2004
- PSNL 2011
- Country
- GLRE Cayman Islands
- PSNL United States
- Employees
- GLRE N/A
- PSNL N/A
- Industry
- GLRE Property-Casualty Insurers
- PSNL Medical Specialities
- Sector
- GLRE Finance
- PSNL Health Care
- Exchange
- GLRE Nasdaq
- PSNL Nasdaq
- Market Cap
- GLRE 439.8M
- PSNL 518.8M
- IPO Year
- GLRE 2007
- PSNL 2019
- Fundamental
- Price
- GLRE $12.24
- PSNL $9.78
- Analyst Decision
- GLRE
- PSNL Strong Buy
- Analyst Count
- GLRE 0
- PSNL 5
- Target Price
- GLRE N/A
- PSNL $8.70
- AVG Volume (30 Days)
- GLRE 126.5K
- PSNL 1.3M
- Earning Date
- GLRE 11-03-2025
- PSNL 11-04-2025
- Dividend Yield
- GLRE N/A
- PSNL N/A
- EPS Growth
- GLRE N/A
- PSNL N/A
- EPS
- GLRE 1.10
- PSNL N/A
- Revenue
- GLRE $695,657,000.00
- PSNL $80,317,000.00
- Revenue This Year
- GLRE N/A
- PSNL N/A
- Revenue Next Year
- GLRE N/A
- PSNL $29.83
- P/E Ratio
- GLRE $11.12
- PSNL N/A
- Revenue Growth
- GLRE 0.97
- PSNL 0.36
- 52 Week Low
- GLRE $12.03
- PSNL $2.83
- 52 Week High
- GLRE $15.82
- PSNL $10.95
- Technical
- Relative Strength Index (RSI)
- GLRE 40.30
- PSNL 64.92
- Support Level
- GLRE $12.03
- PSNL $8.53
- Resistance Level
- GLRE $12.94
- PSNL $10.95
- Average True Range (ATR)
- GLRE 0.27
- PSNL 0.91
- MACD
- GLRE -0.03
- PSNL 0.05
- Stochastic Oscillator
- GLRE 18.63
- PSNL 67.37
About GLRE Greenlight Capital Re Ltd.
Greenlight Capital Re Ltd offers property and casualty reinsurance. Its customers are property and casualty insurers, and Greenlight takes on some of their risk in exchange for insurance premiums. It operates through one operating segment: property and casualty reinsurance. It generates revenue through premiums from reinsurance on property and casualty business assumed and income from investments.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.